Biotechnology News and Research

RSS

NIDDK awards $1.2 million grant to Bolder BioTechnology for long-acting EPO analog program

Bolder BioTechnology, Inc. announced today that it has been awarded a $1.2 million Phase II Small Business Innovation Research (SBIR) grant, entitled "Long-Acting EPO Analog for Treating Anemia Associated with Chronic Kidney Disease," from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of The National Institutes of Health (NIH). Receipt of the entire grant award is contingent upon the achievement of certain research milestones.

18 Sep 2009

Griffin Securities' report features stem cell hypothesis of cancer

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has been featured in an in-depth report by Griffin Securities, a New York-based brokerage firm, highlighting the importance of the role that cancer stem cell (CSCs) targeting technology such as that employed by its lead product candidate, ICT-121, may play in developing future cancer treatments.

18 Sep 2009

Insulin metabolism regulates body's internal clock

While scientists have known for several years that our body's internal clock helps regulate many biological processes, researchers have found that the reverse is also true: Many common biological processes - including insulin metabolism - regulate the clock, according to a new study by investigators at the University of Pennsylvania School of Medicine, the Genomics Institute of the Novartis Research Foundation, and the University of California at San Diego.

18 Sep 2009

Wound Management Technologies acquires BioPharma

Wound Management Technologies, Inc., (OTC Bulletin Board: WNDM) a rapidly growing provider of specialty medical products, announced today that it has completed the acquisition of BioPharma Management Technologies, Inc., a privately held biotechnology company with a platform of proprietary and patented technologies for topical pain management and resorbable orthoses.

18 Sep 2009

GENova Biotherapeutics and Korean university sign strategic partnership agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a LOI for a strategic partnership agreement with the Hospital Medical Information Department of Suncheon Cheongam University in Seoul, South Korea to gain access to its ground-breaking cancer stem cell research information.

18 Sep 2009

InterMune and National Jewish Health to collaborate in the research of idiopathic pulmonary fibrosis

InterMune, Inc. (Nasdaq: ITMN) today announced that it will be collaborating with National Jewish Health(R)( )investigators in order to help further the research of inherited genetic factors that may play a role in idiopathic pulmonary fibrosis (IPF). InterMune will provide researchers at National Jewish with access to DNA collected from patients who participated in the Company's Phase 3 clinical trials in IPF for both pirfenidone (CAPACITY trials) and Actimmune(R) (interferon gamma-1b) (INSPIRE).

17 Sep 2009

4D Medical Systems launches the 4D PhotoStation System in the U.S.

4D Medical Systems, Inc. announced the U.S. launch of the 4D PhotoStation™ System today. The 4D PhotoStation System eliminates the costs and complexities of digital photography in the medical practice while increasing photo-imaging revenue opportunities. Photographic documentation is well known for melanoma, cosmetic procedure before and afters and documenting effects of procedures.

17 Sep 2009

GENova and PacificWave sign engagement agreement

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it has signed an engagement agreement with PacificWave Partners Limited ("PacWave") for raising a minimum of USD5m to the company as well as actively look for potential buy-out and/or acquisition targets.

17 Sep 2009

LAB Research signs exclusive agreement to extend Korean market

LAB Research Inc. ("LAB", "LAB Research" or the "Company"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it has extended its Korean market coverage through a new exclusive agency agreement with Safe Chemicals Co., LTD., a South Korea based consulting company ("Safe Chemicals").

17 Sep 2009

CI Index of ten leading cancer immunotherapy stocks increase by 58% in two months

The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (IMUC.OB) under the leadership of CEO Manish Singh, Ph. D.

17 Sep 2009

GENova Biotherapeutics signs collaboration deal with Beckpharma

17 Sep 2009

Helicos Biosciences to raise $10 million through private placement

Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain new and existing investors, including Atlas Ventures, Flagship Ventures, Highland Capital Partners, Versant Ventures (the “Existing Investors”) and Ron Lowy, the Company’s chief executive officer, to raise approximately $10 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.

17 Sep 2009

Biomagnetics and U.S. Government laboratory continue contract negotiations

Biomagnetics Diagnostics Corp., (PINK SHEETS:BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis, and malaria detection, today announced the Company is in continuing contract negotiations to acquire the rights to Integrated Optical Biosensor System (IBOS) technology developed by one of the U.S. Government’s top national security research institutions.

17 Sep 2009

Growth of biotechnology in LA depends on social cooperation

Stronger connections among businesses, universities and, most importantly, people are necessary if the biotechnology industry is going to survive and thrive in Los Angeles, according to a new study by Professor Steven Casper at Keck Graduate Institute (KGI).

17 Sep 2009

Three senior analysts appointed by Jefferies for healthcare equity research

Jefferies today announced the expansion of its Healthcare Equity Research effort with the hiring of three senior analysts. Corey Davis, PhD has joined as a Managing Director covering Specialty Pharmaceuticals, Thomas Wei will join next month as a Managing Director covering Biotechnology, and Jon Davis Wood will join later this month as a Senior Vice President covering Life Sciences Tools. All three professionals will be based in New York.

17 Sep 2009

Amgen granted approval to use ImmunoGen’s maytansinoid TAP technology

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, today announced that Amgen Inc. has licensed the exclusive right to use the Company’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target found on solid tumors.

17 Sep 2009

Nuveta closes Series A seed financing round for in vitro fertilization research

Nuveta, Inc., a privately held medical device company and global leader in basic in vitro fertilization (IVF) research, announced today that it has closed a Series A seed financing round, solely funded by Vivo Ventures.

17 Sep 2009

Genentech releases Phase III PRIMA study findings

Genentech, Inc., a wholly-owned member of the Roche Group and Biogen Idec, today announced that a Phase III study (PRIMA) showed that patients with follicular lymphoma who continued receiving Rituxan (rituximab) alone after responding to Rituxan and chemotherapy lived longer without their disease worsening (progression-free survival or PFS) than those who did not continue to receive Rituxan.

17 Sep 2009

Bioheart's MARVEL Phase II/III clinical trial successful

Bioheart, Inc. (OTCBB:BHRT), presented positive efficacy data from part 1 of its Phase II/III clinical trial at the Heart Failure Society of America (HFSA) Meeting in Boston, Massachusetts. Thomas Povsic, MD, Ph.D., Assistant Professor of Medicine at Duke University, presented the final data for Part 1 of the MARVEL Phase II/III Clinical Trial as a part of the Late Breaking Clinical Trials Session.

17 Sep 2009

GENova to sign extensive collaboration agreement with Beckpharma

GENova Biotherapeutics Inc. ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening cancers, today announced it is in final negotiations with Beckpharma Ltd. ("Beckpharma") -a pharmaceutical development company also involved in cancer treatments for an extensive collaboration agreement.

17 Sep 2009